JP2022551672A - 乳癌治療法 - Google Patents

乳癌治療法 Download PDF

Info

Publication number
JP2022551672A
JP2022551672A JP2022522322A JP2022522322A JP2022551672A JP 2022551672 A JP2022551672 A JP 2022551672A JP 2022522322 A JP2022522322 A JP 2022522322A JP 2022522322 A JP2022522322 A JP 2022522322A JP 2022551672 A JP2022551672 A JP 2022551672A
Authority
JP
Japan
Prior art keywords
breast cancer
dapanthril
mice
tumor
dapanstril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551672A5 (enExample
Inventor
エー．ディナレロ チャールズ
テンゲスダル アイザック
Original Assignee
オラテック セラピューティクス リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オラテック セラピューティクス リミティド ライアビリティ カンパニー filed Critical オラテック セラピューティクス リミティド ライアビリティ カンパニー
Publication of JP2022551672A publication Critical patent/JP2022551672A/ja
Publication of JP2022551672A5 publication Critical patent/JP2022551672A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2022522322A 2019-10-14 2020-10-12 乳癌治療法 Pending JP2022551672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914833P 2019-10-14 2019-10-14
US62/914,833 2019-10-14
PCT/US2020/055219 WO2021076444A1 (en) 2019-10-14 2020-10-12 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
JP2022551672A true JP2022551672A (ja) 2022-12-12
JP2022551672A5 JP2022551672A5 (enExample) 2023-09-20

Family

ID=75538857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522322A Pending JP2022551672A (ja) 2019-10-14 2020-10-12 乳癌治療法

Country Status (6)

Country Link
US (1) US12582628B2 (enExample)
EP (1) EP4045009A4 (enExample)
JP (1) JP2022551672A (enExample)
CN (1) CN114555053B (enExample)
AU (1) AU2020366300A1 (enExample)
WO (1) WO2021076444A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501657A (ja) * 2022-01-10 2025-01-22 オラテック セラピューティクス， インコーポレイティド 膵臓がんを治療するための方法
CN119744351A (zh) * 2022-03-02 2025-04-01 欧拉泰克治疗公司 用于治疗患有潜能未定的克隆性造血的实体癌患者的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651407B1 (en) 2010-12-15 2016-12-21 Olatec Industries LLC 3-methanesulfonylpropionitrile for treating inflammation and pain
PL2914264T3 (pl) * 2012-11-02 2017-12-29 Merck Patent Gmbh Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
EP3589370A4 (en) * 2017-01-06 2020-11-18 Olatec Therapeutics LLC MULTIPLE SCLEROSIS TREATMENT METHOD
ES2970485T3 (es) 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
WO2019032672A1 (en) * 2017-08-11 2019-02-14 Olatec Therapeutics Llc METHOD OF TREATING SCHNITZLER SYNDROME
CA3087865A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAT. COMMUN., vol. 10:4375, JPN6024034937, September 2019 (2019-09-01), ISSN: 0005519820 *
PROC. NATL. ACAD. SCI., vol. 116, no. 4, JPN6024034935, January 2019 (2019-01-01), pages 1361 - 1369, ISSN: 0005519822 *
PROTEIN CELL, vol. 5(1), JPN6024034936, 2014, pages 12 - 20, ISSN: 0005519821 *

Also Published As

Publication number Publication date
US20220249425A1 (en) 2022-08-11
CN114555053A (zh) 2022-05-27
WO2021076444A1 (en) 2021-04-22
AU2020366300A1 (en) 2022-06-02
EP4045009A4 (en) 2023-11-01
CN114555053B (zh) 2025-09-30
EP4045009A1 (en) 2022-08-24
US12582628B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
US12582628B2 (en) Methods for treating breast cancer
US11857529B2 (en) Methods for treating melanoma
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
EP3664786B1 (en) Method for treating schnitzler's syndrome
EP4338742A1 (en) Application of hydroxyprogesterone caproate in enhancing tumor treatment effect
US20210386736A1 (en) Combination therapy for treating cancer
US20240358669A1 (en) Methods for treating pancreatic cancer
WO2020026102A1 (en) Combination therapy for treating cancer
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
KR102308146B1 (ko) 항암제에 의해 유도되는 이질통의 예방 또는 치료용 조성물 및 이를 이용한 치료방법
WO2023245248A1 (en) Treatment of melanoma
EP4045049A1 (en) Combination therapy for treating a hematological malignancy
HK40040830A (en) Combination therapy for treating cancer
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204